Editorials

Rheumatoid Arthritis Therapy and Joint-replacement Surgery: Are We Making a Difference? S.M. Goodman . 833

Are the New ACR/EULAR Criteria the Ultimate Answer for Polymyalgia Rheumatica Classification? D. Camellino, M.A. Cimmino . 836

Articles

Immunochip Analyses of Epistasis in RA Confirm Multiple Interactions within MHC and Suggest Novel Non-MHC Epistatic Signals
W.H. Wei, C.Y. Loh, J. Worthington, S. Eyre . 839

Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium S. Edginton, C. Hitchon, W. Froese, H. El-Gabalawy . 846

Leflunomide Use and Risk of Lung Disease in RA: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials R. Conway, C. Low, R.J. Coughlan, J.J. Carey . 855

The Longterm Effect of Early Intensive Treatment of Seniors with RA: A Comparison of 2 Population-based Cohort Studies on Time to Joint Replacement Surgery

Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc—positive Carriers Receiving Rituximab for RA: A Retrospective Multicenter Italian Study V. Varisco, M. Viganò, A. Batticiotto, et al . 869

Modified Framingham Risk Score for Systemic Lupus Erythematosus

Copy Number Variation of HLA-DQA1 and APOBEC3A/3B Contribute to the Susceptibility of Systemic Sclerosis in the Chinese Han Population S. Guo, Y. Li, Y. Wang, et al . 880

A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia S. Chartrand, J.J. Swigris, L. Peykova, J. Chung, A. Fischer . 887

Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study
G. Ozen, N. Inanc, A.U. Unal, et al . 893

Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab J. Braun, X. Baraliakos, K.G. Hermann, S. Xu, B. Hsu . 901

Patients with PsA Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin J. Marin, M.L. Acosta Felquer, L. Ferreyra Garrot, S. Ruta, J. Rosa, E.R. Soriano . 907

Longterm Clinical Outcomes in 420 Patients with PsA Taking Anti-TNF Drugs in Real-world Settings
F. Iannone, S. Lopriore, R.ucci, et al . 911

Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial PsA Treated with TNF Inhibitors E. Lubrano, W.J. Parsons, F.M. Perrotta . 918

Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry N. Schlesinger, C.J. Etzel, J. Greenberg, J. Krerem, L.R. Harrold . 924


Pediatric Rheumatology

Inactive Disease in Enthesitis-related Arthritis: Association of Increased Body Mass Index B. Makay, O.A. Gücçemnez, E. Ünsal . 937

A Family History of Psoriasis in a First-degree Relative in Children with JIA: to Include or Exclude? M.O. Chan, R.E. Petty, J. Guzman, for the ReACCCh-Out Investigators . 944

Images in Rheumatology

Synovial Chondromatosis of the Suprapatellar Pouch of the Knee in a Patient with SLE Y. Suyama, S. Nakayama, K. Hagiwara . 948

Free online via JRheum Full Release option

Contents continued on page xx
Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden, July 7-8, 2015

Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA)  

GRAPPA Trainees Symposium 2015: A Report from the GRAPPA 2015 Annual Meeting  
M. Milliken, E. Generali, J. Marin, C.T. Ritchlin ......................... 952

International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update  
J.F. Merola, A.W. Armstrong, A. Saraiya, et al. ......................... 959

Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting  
S.Y. Paek, J.M. Thompson, A.A. Qureshi, J.F. Merola,  
M.E. Husni .............................................. 961

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting  
A.M. Orbai, P.J. Mease, M. de Wit, et al. ................................. 965

Let’s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting  
M. de Wit, W. Campbell, L.C. Coates, et al. .............................. 970

Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting  
A.R. Moverley, R. Waxman, M. de Wit, et al. ............................ 974

GRAPPA 2015 Research and Education Project Reports  

Presidential Round Table: A Report from the GRAPPA Annual Meeting  
D.D. Gladman, P.J. Mease, W.H. Boehncke,  
P.S. Helliwell, K. Callis Duffin ...................................... 986

Correspondence  
Consensus Statement on the Management of Comorbidity in Patients with RA and Psoriasis  
S. Castañeda, E. Loza, E. Daudén, L. Carmona ....................... 990

No Evidence for Depression Screening in RA, Psoriasis, or PsA  
B.D. Thombs, M. Hudson ............................................. 992


Limitations in the Full Reporting of Systematic Literature Review  
B. Haraoui .................................................. 994

Letters  
Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study  
V. Smith, C. Pizzorni, V. Ricci, et al. .................................. 995

Heart Involvement in a Woman Treated with Hydroxychloroquine for SLE Revealing Fabry Disease  
C. Chatre, N. Filippi, F. Roubille, Y.M. Pers ......................... 997

Correction  
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study  
Y. Tanaka, K. Emoto, Z. Cai, T. Aoki, D. Schlichting,  
T. Rooney, et al ............................................. 998

Meetings in Rheumatology .............................................. x